Icotrokinra: clinical trials recruiting now
3
Recruiting trials
6
Conditions studied
27
US states with sites
33
Countries
FDA drug label
- FDA-approved
- Yes. Icotrokinra appears in the FDA drug-label database. Marketed as ICOTYDE.
FDA-approved use
ICOTYDE is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. ICOTYDE is an interleukin-23 (IL-23) receptor antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. ( 1 )
Phase breakdown
Phase 2 1
Phase 3 3
Conditions being studied
| Condition | Trials |
|---|---|
| Arthritis, Psoriatic | 1 |
| Colitis, Ulcerative | 1 |
| Crohn Disease | 1 |
| Crohn's disease | 1 |
| Psoriasis | 1 |
| Ulcerative colitis | 1 |
Recruiting trials involving Icotrokinra
- A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
Common questions
Is Icotrokinra FDA-approved?
Yes, marketed as ICOTYDE.
How many recruiting trials involve Icotrokinra?
3 recruiting trials across 6 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.